Is Capricor Therapeutics profitable?

Capricor Therapeutics is not currently profitable: it reported a net loss of $114.6M over the trailing twelve months, a -736.6% net margin.

What is Capricor Therapeutics's earnings per share?

Capricor Therapeutics's diluted EPS over the trailing twelve months is $-2.32.

Where does Capricor Therapeutics's income statement data come from?

Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Capricor Therapeutics CAPR Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$0-100%	$22.27M-11.5%	$25.18M—	——
Research and development	$84.45M+69.0%	$49.97M+37.1%	$36.45M+67.1%	$21.82M+60.8%
General and administrative	$23.69M+59.3%	$14.87M+16.1%	$12.81M+22.8%	$10.43M+37.0%
Other operating expenses	$108.14M+66.8%	$64.83M+31.6%	$49.26M+52.7%	$32.25M+52.2%
Total operating expenses	$108.14M+66.8%	$64.83M+31.6%	$49.26M+52.7%	$32.25M+52.2%
Operating income	-$108.14M-154%	-$42.56M-76.8%	-$24.08M+18.9%	-$29.7M-41.8%
Interest income	$6.26M+184%	$2.2M+27.4%	$1.73M+231%	$521.54K+808%
Other income (expense), net	——	$2.1M+17.2%	$1.79M+164%	$677.85K-26.0%
Gain (loss) on disposal of assets	——	-$112.81K—	——	——
Income before income taxes	——	-$40.47M—	——	——
Income tax expense	——	$1.6K—	——	——
Net income	-$105.04M-160%	-$40.47M-81.6%	-$22.29M+23.2%	-$29.02M-44.9%
Diluted earnings per share	-$2.26-96.5%	-$1.15-35.3%	-$0.85+28.0%	-$1.18-35.6%
Basic earnings per share	-$2.26-96.5%	-$1.15-35.3%	-$0.85+28.0%	-$1.18-35.6%
Weighted-average shares, diluted	183.5M+39.6%	131.5M+27.5%	103.2M+5.7%	97.6M+6.9%
Weighted-average shares, basic	183.5M+39.6%	131.5M+27.5%	103.2M+5.7%	97.6M+6.9%
Investment and other income	$6.26M+184%	$2.2M+27.4%	$1.73M+231%	$521.54K+808%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$105.79M-167%	-$39.68M-79.1%	-$22.16M+23.4%	-$28.91M-44.4%
Net unrealized gains (losses) on securities still held	-$743.8K-194%	$791.14K+506%	$130.57K—	——
Membership and other income	$45.42K+508%	$7.47K-89.0%	$67.66K—	——
EBIT	-$108.14M-154%	-$42.56M-76.8%	-$24.08M+18.9%	-$29.7M-41.8%
EBITDA	-$106.25M-158%	-$41.14M-78.8%	-$23.01M+21.1%	-$29.16M-40.9%
EBITDA	-$106.25M-158%	-$41.14M-78.8%	-$23.01M+21.1%	-$29.16M-40.9%
EBIT	-$108.14M-154%	-$42.56M-76.8%	-$24.08M+18.9%	-$29.7M-41.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Capricor Therapeutics profitable?: Capricor Therapeutics is not currently profitable: it reported a net loss of $114.6M over the trailing twelve months, a -736.6% net margin.
What is Capricor Therapeutics's earnings per share?: Capricor Therapeutics's diluted EPS over the trailing twelve months is $-2.32.
Where does Capricor Therapeutics's income statement data come from?: Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.